|
|
本帖最后由 不怕开水烫 于 2026-2-25 13:36 编辑
PulseMedica has achieved several key milestones recently, including:
• Raised $17M+ USD since inception.
• Recently closed $7.5M USD to complete its first-in-human (FIH) floater treatment study ($1.5M USD remaining).
• Rapidly advancing towards FIH floater treatment.
CEO & Co-Founder Nir Katchinskiy has been selected to present PulseMedica at LSI USA ’26 this March 16–20 in Dana Point, California.
完成首次人体试验目前还需额外的150万美元。CEO兼创始人Nir将于今年3月16日到20日受邀在加州参加USA LSI大会。
|
|